Stroke
Conditions
Interventions
Experimental group:intravenous infusion chlorpromazine 50 mg and promethazine 50 mg
control group:standard treatment
Sponsors
Beijing Luhe Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 80 years old; (2) clinical diagnosis of AIS; (3) NIHSS score 6 to 25; (4) patients with time from onset to treatment <=24 hours. (5) did not receive endovascular treatment (EVT); (6) pre-stroke mRS <=2; (7) informed consent provided by participant or legally authorized representative.
Exclusion criteria
Exclusion criteria: (1) rapid and spontaneous relief of symptoms: NIHSS score reduced to <6; (2) hemodynamic instability, including low systolic blood pressure (SBP) and SBP <=100 mmHg despite standard treatment; (3) medical history of Parkinson's disease, Parkinson's syndrome, neuroleptic malignant syndrome, basal ganglia disease and epilepsy; (4) allergy to phenothiazines; (5) acute myocardial infarction, acute cardiac insufficiency and/or serious arrhythmia; (6) participant in another ongoing clinical trial; (7) life expectancy of fewer than 1 year due to comorbidities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90day mRS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| 90day mRS 0-2 rate; | — |
Countries
China
Contacts
Public Contact???
Beijing Luhe Hospital, Capital Medical University
Outcome results
None listed